INTRODUCTION
Genome-wide association studies (GWAS), DNA sequencing studies, and other genomic studies are finding an increasing number of genetic variants associated with clinical phenotypes that may be useful in developing diagnostic, preventive, and treatment strategies for individual patients. Conceptually, one can view these genetic variants along a continuum between common polymorphisms and rare or private mutations ]. This range of allele frequencies has implications for the discovery of such variants in different populations, the study of such variants with regard to their clinical implications, and the detection and interpretation of specific variants in a given individual. The vast amount of human medical genetics research conducted over the last few decades began primarily with the discovery of mutations in genes responsible for Mendelian diseases. More recently this research expanded to include the common variation associated with multifactorial phenotypes discovered through GWAS . Clinical genetic testing has been used in a specialized clinical genetics setting for over 50 years, providing specific molecular diagnoses for thousands of individuals with rare single gene and chromosomal disorders. Somatic tumor variants are now increasingly assayed in order to target chemotherapy [McLeod, 2013] and germline pharmacogenomic variants are beginning to be incorporated into routine clinical practice in certain scenarios [Relling and Klein, 2011] . However, despite an increasing number of characterized variants from GWAS studies, few common variants have been integrated into routine clinical practice. The reasons for this are several, but two of the most significant are limited evidence about the clinical implications of the variants and a lack of a comprehensive knowledge base that captures genetic variants, their phenotypic associations, and other pertinent clinically relevant information that is openly accessible to clinical groups attempting to interpret sequencing data Manolio et al., 2013] .
despite an increasing number of characterized variants from GWAS studies, few common variants have been integrated into routine clinical practice.
The reasons for this are several, but two of the most significant are limited evidence about the clinical implications of the variants and a lack of a comprehensive knowledge base that captures genetic variants, their phenotypic associations, and other pertinent clinically relevant information that is openly accessible to clinical groups attempting to interpret sequencing data.
Data on the clinical implications of genetic variants are currently contained in a patchwork of non-standardized repositories maintained by individual scientists, academic institutions, laboratories, government entities, and industry and are not easily accessible to health care providers and health care systems. Making this information accessible and useful for clinical care will require systematic collection, extraction, evalu-ation, and synthesis of these findings followed by standardized representation of the information in queryable databases, along with tools permitting userdefined filtering. It will be important to compile the available evidence and develop consensus views from the clinical, genetics, and laboratory communities on what variants are actionable and the clinical actions to be taken. This information must then be made available to clinicians through clinical decision support tools embedded in electronic health records (EHR) [Starren et al., 2013] .
As the field of medicine begins to incorporate genome-scale analysis into clinical care, approaches need to be developed for collecting and characterizing data on the clinical implications of variants, developing consensus on their actionability, and making this information available for clinical use. The National Human Genome Research Institute (NHGRI) and the Wellcome Trust thus convened a workshop to consider the processes and resources needed to: (1) identify clinically valid genetic variants; (2) decide whether they are actionable and what the action should be; and (3) provide this information for clinical use. The following sections summarize the discussion and the workshop recommendations (see Box 1).
EXISTING GENETIC VARIATION RESOURCES
Several existing resources provide some of the underlying data required to characterize genetic variants along the evidence continuum (Table I) . For example, dbSNP is a catalog of short genetic variation, OMIM contains clinical descriptions and genetic variation primarily related to Mendelian diseases, and the NHGRI GWAS Catalog curates
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Box 1 Characterizing and Displaying Genetic Variants for Clinical Action Workshop Recommendations
Existing Genetic Variation Resources
Hold a workshop or convene a working group to identify reasonable technical standards for exchange of genetic variant and clinical data to maximize exchange of among existing databases. Coordinate with US and UK agencies, such as Agency for Healthcare Research and Quality (AHRQ), the Office of the National Coordinator for Health Information Technology (ONC), Department of Veterans Affairs (DVA), National Health Service (NHS), commercial electronic health record (EHR) vendors, and other relevant organizations to address data interoperability and viable approaches for integration of genomic information and actionable variants into a variety of EHR systems. Facilitate the clinical annotation of genes and germline and somatic variants in relation to specific traits (including specificity, sensitivity, prevalence, positive and negative predictive values, and penetrance). Capture of penetrance data from exome chip studies may be a good opportunity to capture information on the "most common of the rare" variants. Ensure that (1) ClinVar and similar resources capture genetic variants of unknown significance (VUS) and isolated reports of variant-condition associations identified through clinical sequencing projects, and (2) computer programs are developed to enable clinical sequencing labs to efficiently transmit data to such resources.
Identifying Genetic Variants for Potential Clinical Action
Support and expand research to determine clinical validity and utility/actionability of SNP and structural genetic variants. Design studies to ensure that clinically valid variants for which actionability is unknown are appropriately stratified and have identified research pathways for determining actionability. Ensure that studies of gene-disease and gene-drug associations in diverse populations are funded. Support functional and other follow-up studies on novel variants found in specific genes with known utility (e.g., determine the consequence of every BRCA1 variant) to generate data to support better interpretation of variants of uncertain significance. Explore mechanisms to facilitate communication between labs studying specific genes with potentially clinically relevant variants and researchers and clinicians with family, phenotype and other clinical information willing to partner to study the function of the genes and variants. Maximize interactions among epidemiologists, bioinformaticians, and genomic scientists to facilitate obtaining needed information on clinical validity and utility. For example, develop training programs that bring these three disciplines together to tackle specific aspects of the pipeline needed to identify actionable variants and move them into the clinic. Serve as a "convener" in conjunction with other NIH Institutes and Centers, professional organizations, and other groups to build consensus, prioritize and publicize recommendations regarding clinical validity and utility/actionability.
Creating a Translation Loop for Genomic Medicine
Create and support a coordinated resource to extend Ensembl, ClinVar, and other databases for use in clinical care by providing relevant phenotype information, other clinical annotation, and suggestions regarding clinical utility/actionability. Such a resource could help bridge the gap between researchers and primary care clinicians, who will need user-friendly clinical support tools and/ or an EHR integration layer to readily utilize these data in clinical care. Collaborate with data warehouses (e.g., Medco) on large-scale studies to better evaluate outcomes of specific uses of genomic variants in clinical care. Develop a process to identify research questions that could be answered using data warehouses. Consider supporting competitions that promote development of algorithms for interpreting genomic variants and compare algorithm performance, such as the Critical Assessment of Genome Interpretation (CAGI; http://genomeinterpretation.org/) effort. Encourage the dissemination of decision support logic and interpretive tools, including making a publicly available library, to enable diverse EHR systems to use the same logic and tools when developing clinical decision support tools. Develop and test innovative genetic education tools for providers specifically focused around the appropriate use of genomic variants. Develop approaches for long-term follow-up of patients with rare variants of interest to better understand the relationship of these variants to disease and other phenotypes, leveraging existing resources with healthcare systems (e.g., payer information, NHS records). Catalyze discussion with the US Office for Human Research Protections (OHRP) and the UK National Research Ethics Service (NRES) regarding institutional review board guidance on boundaries and synergy between clinical care and research. Conduct policy analyses to better understand the perspectives of relevant organizations (e.g., FDA, CMS, NICE, UKGTN, and professional organizations such as ACMG, CAP, and AMP) regarding using genetic variant information to inform clinical care. significant SNP-trait associations from genome-wide association studies. There are also approximately 1,600 locusspecific databases that curate clinical information on specific genes or diseases, although they vary in the types of data included and nomenclature followed (http://www.centralmutations.org/Lsdb. php). The National Center for Biotechnology Information (NCBI) has developed a new database, ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), existing databases should be maximized to ensure comparability and avoid duplication. In addition, none of these resources are currently designed to interact with EHR systems, meaning clinicians would have to access the information by interrupting their clinical workflow-a known barrier to use [Ross, 2009] In the case of rare diseases in which formal CU may be difficult to assess, the diagnostic information can still guide management of the patient, which is a type of clinical utility [Grosse et al., 2010] . The discussion of what evidence is needed for CU frequently centers on whether a clinician should order a particular genetic assay to make a diagnostic or therapeutic decision, and does not address the question of what a clinician could or should do if that information were already available. The latter is important to consider under several possible future scenarios; people may order their own sequence from commercial vendors and then present their clinician with the findings for interpretation or participation in a research orientated biobank may lead to extensive genetic variants including sequence data being available and potentially actionable. The Clinical Pharmacogenetic Implementation Consortium (http://www.pharmgkb.org/page/cpic GeneDrugPairs) has created a set of pharmacogenetic guidelines based on this principle. The concept of "personal utility" has been put forward as another facet of medical decision-making regarding the use of genetic testing [Foster et al., 2009] . For example, the specific genetic etiology of a rare disorder can have immense value to families regardless of the ability to intervene in a particular condition. Similar "personal utility" might be derived from more common genetic variation, such as APOE status and Alzheimer disease risk [Roberts et al., 2011] and other profiles of variants with small contributions to multifactorial disease [Gollust et al., 2012] , but this type of information is by definition highly context-dependent and requires input from the patient regarding whether such information is desired. An intermediate category between CV and CU has been termed clinical actionability (see Fig. 1 ). This can be applied to variants having either proven CU or evidence sufficient to indicate how existing variant information could or should be used clinically though insufficient to establish CU unequivocally [Berg et al., 2011] . This concept of actionability also allows flexibility for clinicians or even institutions to tailor their use of variant information to a particular patient, clinical setting, or local standard of practice. However, lack of clear clinical utility also means that an action taken in response to the finding of a genetic variant may in fact have detrimental outcomes. Furthermore, the definition of "actionable" can range from a broad inclusion of variants with possible "personal utility" to a more narrow definition of variants that have well-established implications for the management of the individual patient.
As a practical matter, the variants identified in an individual patient will fall into two broad categories: "known" genetic variants that have been observed previously and "novel" genetic variants that have not been observed before and may be unique to that individual or private to his or her family members. With regard to "known" genetic variants, the existence of prior information about these variants should in theory facilitate the annotation of their clinical significance or lack thereof, whereas "novel" genetic variants may require quite different methods for determining their clinical relevance. Many of the databases of known genetic variants listed in Table I are primary data archives, and thus maintain experimental results regarding genetic variants and their phenotypic correlations rather than curators' interpretation of these data. However, numerous medical centers and research programs are beginning to evaluate these databases and other pieces of information to explore the use of such variants in clinical care, and many are developing approaches for identifying variants to be assayed and the actions to be recommended when they are detected (see Table II for a brief description of some of these programs and approaches). These groups are often evaluating the same assays, reviewing the same literature, and assessing the same evidence. In addition, efforts to identify variants relevant to drug response have been ongoing through the National Institute of General Medical Sciences (NIGMS)-led Pharmacogenomics Knowledge Base (PharmGKB) and Pharmacogenomics Research Network (PGRN) and independent research groups such as Coriell's Pharmacogenomics Advisory Group. Unifying these often isolated efforts and developing a consensus framework for evaluating existing data might reduce duplication of effort and eventually speed adoption of actionable genetic variants into clinical practice.
Although significant progress has been made identifying disease variant associations, a key barrier to the identification of variants for clinical use is the lack of clinical translational research beyond this initial identification of an association to assess the risks, costs, and health benefits of utilizing genomic information in the practice of clinical medicine. The importance of this problem was evident from an informal poll of our workshop attendees showing little consensus on the appropriateness of using genetic variant information in a variety of clinical scenarios and from the discordance among genetics experts The concept of "personal utility" has been put forward as another facet of medical decision-making regarding the use of genetic testing. For example, the specific genetic etiology of a rare disorder can have immense value to families regardless of the ability to intervene in a particular condition.
ARTICLE asked to assess the importance of returning specific secondary findings after clinical sequencing [Green et al., 2012] . The 2011 NHGRI strategic plan [Green and Guyer, 2011] identifies the need for funding clinical research to accelerate the pace of knowledge generation needed to increase the clinical use of genetic information. Given the large number of variants that currently have limited evidence of actionability, despite their clinical validity [Berg et al., 2011] , clear pathways will need to be developed for providing the evidence to move them into the [Fullerton et al., 2012] . The current focus is to define an initial set of variants that are potentially useful in clinical practice for purposes such as assessment of genetic risk for complex disorders or selection or dosing of drugs. This initial set will focus on common disease risk variants and pharmacogenomic variants for which eMERGE sites expect to have data International Collaboration for Clinical Genomics (ICCG)
Participating in the ClinGen program. Curation and evidence-based review of structural and sequence-level variant data deposited within ClinVar to assign consensus annotation of variants with regard to their clinical significance (e.g., "pathogenic," "benign," etc.) and standardize clinical interpretations Clinical Pharmacogenetics Implementation Consortium, CPIC actionable range or demonstrate definitively their lack of clinical utility. Again, a critical component of that pathway is deposition of primary data in welldefined, standardized formats to public databases. To support standardized assessment of information about human variation, it is critical that both the primary data and the current interpretation of those data be freely accessible. Processes and decision support tools can then be applied to the existing data to identify which variants are clinically actionable and provide these variants and supporting information for clinical use as appropriate.
In addition to devising a plan to accumulate evidence of actionability for known clinically valid variants, additional effort must be dedicated to expand the set of current associations beyond populations of European ancestry. There is a paucity of data on associations in non-European ancestry populations. Differences in allele frequencies and linkage disequilibrium patterns across ancestry groups [The International Hap-Map Consortium, 2005; Abecasis et al., 2010; Altshuler et al., 2010] , as well as major differences in disease burden and severity , make research in these under-studied populations a critical need. Further, determining the effect of rare variants on gene function is essential to determining the clinical impact of these variants [Marian, 2012] . This might be addressed by enhancing communications between researchers who identify rare or unique variants in well-phenotyped individuals and families and researchers with interests in the specific gene(s) implicated in these conditions. Another critical group of stakeholders are the diagnostic laboratories performing clinical molecular tests for rare disorders. These clinical laboratories often hold a wealth of information about variants detected in specific genes and their interpretation of the pathogenicity of those variants. Thus, development of data-sharing models that protect patient privacy could enhance communication regarding the clinical significance of genetic variants. This model was used to create the International Standards for Cytogenomic Arrays (ISCA) Consortium database where multiple academic and commercial laboratories contribute data on copy number variants (CNVs) and associated phenotypes. To date data on over Thus, development of data-sharing models that protect patient privacy could enhance communication regarding the clinical significance of genetic variants. This model was used to create the International Standards for Cytogenomic Arrays (ISCA) Consortium database where multiple academic and commercial laboratories contribute data on copy number variants (CNVs) and associated phenotypes.
32,000 patients has been collected allowing rapid identification of novel CNVs associated with a range of disorders. Together, these efforts would create a so-called "translational loop," from bench to bedside and back again, as described below.
CREATING A TRANSLATION LOOP FOR GENOMIC MEDICINE
To achieve more effective translation of genomic variant information into clinical practice requires not only a "push" to move evidence-based information generated in the laboratory into the clinic, but the ability to "pull" or extract information from clinical data systems to assess the impact of implementation of that research on real world clinical outcomes and effectiveness (see Fig. 2 ). This assessment should lead to further research to validate or expand evidence and, where appropriate, modify clinical practice, creating the translation loop. To ensure this translation loop is successful requires the identification of novel research approaches that may be purposed to answer specific clinical questions. As noted above, the spectrum of genetic variation from common to rare (or private) variants will dictate the approaches that can be used to determine the clinical significance and actionability of different types of genetic variants. For example, pharmacogenomic alleles that are part of the natural human population variation should be amenable to large prospective studies that can formally assess the evidence for clinical utility such as that being done by the Electronic Medical Records and Genomics pharmacogenomics project (eMERGE-PGX) [Gottesman et al., 2013] . Although randomized control trials have been the standard in evaluating clinical effectiveness and should continue to be utilized to better understand the impact of various aspects of genomic medicine, they can be time consuming and expensive. In addition, the application of clinical trial results with their tight controls to the complicated milieu of routine patient care is difficult [Hoes, 2009] . Other methodologies that produce useful observational data need to be considered. The use Although significant progress has been made identifying disease variant associations, a key barrier to the identification of variants for clinical use is the lack of clinical translational research beyond this initial identification of an association to assess the risks, costs, and health benefits of utilizing genomic information in the practice of clinical medicine. of extant publicly accessible data warehouses (such as was done for the Medco-Mayo warfarin effectiveness study [Epstein et al., 2010] or data from consumer genomics companies are such approaches. In order to take advantage of these data warehouses and other clinical data repositories, it is important to develop systems that can retrieve information about defined outcomes of interest from these sources and other transactional data warehouses (e.g., payer databases, pharmacy databases). Information from these sources can be used to assess the use of a given variant by clinician; identify individual and organizational factors that facilitate or impede the actual use of the variant; assess the effect on health behaviors, compliance, and other medical outcomes from the patient perspective; estimate the effect on cost of care; and compare decision-making algorithms to determine which are best for clinical use.
Often clinical implementation does not occur until practice guidelines have been developed by leading professional organizations; therefore, movement through the translational loop may be prompted by observational studies which facilitate the use of novel data in a real world setting. Data from observational studies, rather than clinical trials, may then provide both the data and impetus for large scale clinical implementation. Alternatively, these approaches could be used as preliminary, low cost methods to identify potential signals that could be prioritized for examination in more traditional research designs. Dissemination of these novel research approaches would avoid each health care system having to create its own specific algorithm or educational resources for the use of common genetic variants in clinical care, allowing the organizations to focus on the processes needed to implement this in clinical care. This approach could also allow the testing of various types of implementation approaches to see which are more effective in the clinic, provided that such studies are performed systematically and outcomes are rigorously measured. These types of novel approaches are probably most applicable to common variants responsible for pharmacogenomic traits and risk for multifactorial diseases.
Another benefit of a translation loop is the ability to more rapidly understand the prevalence and clinical impact of rare variants that are expected to be identified in genes of interest as next generation sequencing is increasingly deployed in clinical and research settings. This is of particular importance if rare variants with high clinical impact are to be identified and used to improve patient care. However, the assessment of rare variants in clinical medicine may require different methods than those used to assess pharmacogenomic variants or common risk factors for multifactorial diseases. There are two contexts in which rare variants might be evaluated:
(1) in the diagnostic evaluation of a person with a suspected single gene disorder, and (2) as part of a collection of "incidental" or "secondary" findings from a genome-scale sequencing assay. In the molecular diagnostic setting, the goal is to identify the single variant or combination of variants that explains the patient's presenting phenotype. In contrast to the diagnostic setting, where there is a substantial a priori probability of a genetic etiology, rare variants identified as genomic incidental or secondary findings are problematic because in the absence of a family history or phenotypic features, the a priori probability that the individual is affected with a particular single gene disorder caused by a given variant is very small. Thus, evidentiary standards may be different for rare variants depending on the clinical context.
Various types of evidence are used to define whether a given rare variant is likely to provide such an explanation for a patient's diagnosis, including the allele frequency in control populations, the effect of the variant on the translated protein compared to the types of changes that typically cause the disorder, in silico predictions that take into account evolutionary conservation and protein structure, and family segregation studies. The final element needed to Various types of evidence are used to define whether a given rare variant is likely to provide such an explanation for a patient's diagnosis, including the allele frequency in control populations, the effect of the variant on the translated protein compared to the types of changes that typically cause the disorder, in silico predictions that take into account evolutionary conservation and protein structure, and family segregation studies.
close the translation loop is the capability to aggregate assertions made by researchers and molecular diagnostic laboratories regarding the pathogenicity (or lack thereof) for particular variants in order to provide updated knowledge in an efficient way to the central databases that store information on genotypes and phenotypes (such as those identified in Table I .html] may impact the ability to pursue this type of research. One aspect of this proposal is that written consent for research use of any biospecimens collected for clinical purposes would be required. The impact of current and proposed new policies on the use of genetic variants in clinical practice will need to be studied. Exploration of these and other policy issues with institutions responsible for the oversight of human subjects research such as the Office for Human Research Protections (OHRP)/National Research Ethics Service (NRES) and their international counterparts is needed to try to harmonize approaches to these types of studies.
CONCLUSIONS
GWAS, DNA sequencing studies, and other genomic studies are producing a profusion of genetic variants that are or may be associated with clinical phenotypes. For each of these variants it is important to determine population-specific frequencies; identify which variants have clinical effects and characterize those effects; and follow variant carriers over time to study natural history and measure the impact of clinical intervention that result from knowledge of these variants. To minimize the risk of being overwhelmed by the number of variants that need to be evaluated for potential clinical actionability, strategies to prioritize investigation are needed. This prioritization should include an upfront assessment of the likelihood of clinical value based on standardized frameworks such as the method proposed by Berg et al. [2011] . The scalability of such prioritization will be challenging because each variant will most likely need a detailed review of available evidence for multiple clinical scenarios [Fullerton et al., 2012] . Classification of genes or variants into such schema should be vetted by larger groups of experts and, ultimately, professional societies can review these evidence syntheses to generate clinical practice guidelines on which clinical decision support tools can be built. Speeding the adoption of actionable genetic findings for use in clinical care first requires the development of a dynamic and comprehensive resource of clinically relevant genetic variants. To meet this need, the NHGRI issued a funding opportunity titled "Clinically Relevant Genetic Variants Resource (CRVR): A Unified Approach for Identifying Genetic Variants for Clinical Use (U01)" (http:// grants.nih.gov/grants/guide/rfa-files/ rfa-hg-12-016.html). CRVR has since evolved into the Clinical Genome Resource (ClinGen)-a collaboration between CRVR grantees and the International Collaboration for Clinical Genomics (ICCG formerly the ISCA referenced above) to develop a pipeline for the submission by clinical laboratories of sequence variants and related data to a central database (ClinVar), curate these variants with clinical and functional data and improve algorithms to aid variant interpretation, develop a consensus process to bin genes and variants into categories of clinical actionability, identify clinically relevant variants for consideration for clinical use, and systematically disseminate this information including creating a resource that is compatible with standards based electronic health record systems. Engaging the numerous individual research efforts and relevant stakeholders including genetics researchers, bioinformaticians, clinicians and medical institutions, professional societies, and regulatory agencies, is paramount for shaping such a comprehensive and useful resource.
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